Clinical Trial
Accepted on 05 May 2026
Disease outcomes with ublituximab in treatment-naïve participants: Subpopulation analyses of the Phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
in Multiple Sclerosis and Neuroimmunology